Safety, tolerability, and biodistribution of [89Zr]Zr-DFO-APAC (Phase 0) in subjects with peripheral arterial occlusive disease / critical limb ischemia (PAOD/CLI) and healthy volunteers – an open label PET study (CHASE-study)
Phase 1
Recruiting
- Conditions
- Critical limb ischemia, Peripheral arterial occlusive diseaseMedDRA version: 21.1Level: LLTClassification code: 10058072Term: Critical limb ischaemia Class: 10047065MedDRA version: 21.1Level: PTClassification code: 10062585Term: Peripheral arterial occlusive disease Class: 100000004866Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
- Registration Number
- CTIS2023-505287-11-01
- Lead Sponsor
- Aplagon Oy
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method